Skip to main content

Advertisement

Fig. 1 | Molecular Cancer

Fig. 1

From: Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2

Fig. 1

VASH2 expression is associated with gemcitabine resistance in pancreatic cancer. Kaplan-Meier survival analysis results of 102 cases of pancreatic cancer. a survival analysis of patients with negative/weak VASH2 staining tumors treated with or without gemcitabine chemotherapy. b survival analysis of patients with middle/strong VASH2 staining tumors treated with or without gemcitabine chemotherapy. c survival analysis of patients treated with gemcitabine chemotherapy with negative/weak or middle/strong VASH2 staining tumors. d survival analysis of patients who received no chemotherapy with negative/weak or middle/strong VASH2 staining tumors

Back to article page